The Life Sciences team advised SpringWorks Therapeutics (Nasdaq: SWTX) on its clinical trial collaboration agreement with Allogene Therapeutics, Inc. (Nasdaq: ALLO). The agreement will evaluate ALLO-715, Allogene’s investigational anti-B-cell maturation antigen (BCMA) AlloCAR T™ therapy in combination with SpringWorks’ investigational gamma secretase inhibitor (GSI), nirogacestat, in patients with relapsed or refractory multiple myeloma.
SpringWorks is a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer. Allogene is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer.
Under the terms of the agreement, Allogene will sponsor and conduct the Phase 1 study to evaluate the safety, tolerability and preliminary efficacy of the combination, and will assume all development costs associated with the study. Allogene and SpringWorks will form a joint development committee to oversee the clinical study, which is expected to commence in the second half of 2020 pending discussions with regulators.
The Goodwin team was led by Chris Denn.